| Name | JD-5037 |
| Description | JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM. |
| Animal Research | Mice: JD-5037 is formulated in vehicle (V; 1% Tween80, 4% DMSO, 95% Saline). Obese mice are treated chronically (28 d) with vehicle (V; 1% Tween80, 4% DMSO, 95% Saline), JD5037, or SLV319 at a dose of 3 mg/kg, i.p. Body weight and food intake are monitored daily. Mice are euthanized by cervical dislocation under anesthesia; the brain, hypothalamus, liver, and combined fat pads are removed, weighed, and snap-frozen, and trunk blood is collected for determining the endocrine and biochemical parameters |
| In vivo | JD5037, when administered at a dosage of 3 mg/kg/day intraperitoneally (i.p.), effectively induces uniform reductions in body weight and mitigates high-fat diet (HFD)-induced hyperglycemia, hepatic injury, and steatosis in obese Magel2-null mice. Likewise, oral administration of JD5037 (3 mg/kg/day, p.o.) significantly diminishes tumor size and eliminates tumors in DEN-treated mice. Moreover, JD5037 reduces anandamide (AEA) levels in hepatocellular carcinoma (HCC) samples from mice. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.49 mM), Sonication is recommended.
DMSO : 240 mg/mL (419.21 mM), Sonication is recommended.
|
| Keywords | JD-5037 | JD5037 | Inhibitor | inhibit | CB1R | CB | CannabinoidReceptor | Cannabinoid Receptor |
| Inhibitors Related | RTICBM-189 | β-Caryophyllene | CB2 modulator 1 | Pregnenolone | Pregnenolone acetate | CB1 antagonist 2 | Dehydroabiethylamine | CB2 receptor agonist 2 | AM-1235 | 2,3-Butanediol | Drinabant | AM281 |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Anti-Obesity Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Metabolism Disease Compound Library |
United States
